BLFS · Biolife Solutions Inc
$37.30
+0.52 (+1.41%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$1.92B
Shares
48.91M
Volume · Oct 2
2.85M
Avg daily vol (3M)
1.07M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$37.30
Open$37.02
Day$36.83–37.98
52W close$18.15–39.22
Avg vol 30d997K
Short int3.9M · 7.9% float · 4.5d
Short vol23%
Last earningsMay 7, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
call held May 7, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+44.0%
Trailing year
Short interest
7.9%
Latest settlement · 4.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Moderate
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+40%
above
Price vs 50-day avg
+5%
above
RSI (14)
53
neutral
MACD trend
Negative
52-week position
91%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+5%
trailing
6-month return
+85%
trailing
YTD return
+54%
this year
Relative strength
+73%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $36 › 200d $27 — 50d above 200d
Institutional flow
Flat
1 of 216 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
7.94% of float · ▼ -1.1% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
216 holders — near 3-yr high, broad support
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
+29%
Y/Y
Gross margin
65%
contracting
EPS growth
+77%
Y/Y
Free cash flow
$10.6M
Valuation
P/E 33.8
in line
Balance sheet
$28.0M
net cash
Quant / Vol
risk profile
Volatility
44%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
2.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
Revenue
· full year 2026
Initiated
$112.5M – $115M
prior FY $96.21M
midpoint +18.2% Y/Y
Guided vs delivered
· last 2 settled
Total 2023 revenue
full year 2023
guided $144M – $158M
$68.02M
Miss −55.0%
Total revenue
for 2021
guided $115M – $119M
$119.16M
Beat +1.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+40%
Bullish
Price vs 50-day avg
+5%
Bullish
RSI (14)
53
Neutral
MACD trend
Negative
Bearish
52-week position
91%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $36 › 200d $27 — 50d above 200d
Institutional flow
Flat
1 of 216 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
7.94% of float · ▼ -1.1% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
216 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $18
Now $37 · 91%
Range high $39
vs 200-day avg +40%
vs 50-day avg +5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 13.5M | six months ended June 30, 2026 | — |
| Adjusted EBITDA % of Revenue non-GAAP | 24% | Six Months Ended June 30, 2026 | — |
| Adjusted Gross Margin non-GAAP | 65% | Six Months Ended June 30, 2026 | — |
| Adjusted Gross Profit non-GAAP | $36.26M | Six Months Ended June 30, 2026 | — |
| Adjusted Net Income non-GAAP | $6.3M | Six Months Ended June 30, 2026 | — |
| Adjusted Operating Expenses non-GAAP | $32.2M | Six Months Ended June 30, 2026 | — |
| Adjusted Operating Income / (Loss) non-GAAP | $4.07M | Six Months Ended June 30, 2026 | — |
| Biopreservation media embedded in commercial CGTs | 18 | as of June 30, 2026 | — |
| Biopreservation media ongoing commercially sponsored clinical trials in the U.S. | 250 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BLFS
this stock
Biolife Solutions Inc
|
$1.92B | +54.3% | +28.9% | 33.8 | 7.9% |
|
ISRG
Intuitive Surgical Inc
|
$143.14B | -30.8% | +20.5% | 46.5 | 2.3% |
|
BDX
Becton Dickinson & Co
|
$49.57B | — | +8.2% | — | 4.2% |
|
MDLN
Medline Inc.
|
$45.62B | -15.2% | +11.5% | — | 3.1% |
|
RMD
Resmed Inc
|
$32.02B | -9.1% | +13.4% | 21.3 | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BLFS | -3.1% | +5.0% | +85.5% | -4.0% | +54.3% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -2.9% | +5.4% | +73.3% | -4.9% | +41.4% |